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EDITORIAL COMMENTS
Urological epidemiology has evolved since the orig-
inal UDA paper on LUTS/BPH was published in
2005.1 That work by Wei et al has been a valuable
resource with more than 500 citations. Today health
services and outcomes research programs are ubiq-
uitous and ever popular. The ability to obtain,
create and analyze big data sets continues to
expand, as does the workforce with the training and
desire to answer important questions and generate
new knowledge. One may wonder whether the UDA
will have as much impact today has it did in 2005.
The current study shows the promise and power
of the UDA. The UDA enabled collaboration of ex-
perts in the field; researchers were brought together
to study urological disease. The UDA facilitated
access and analysis of high quality longitudinal data
which are available to anybody and yet it has
barriers. Optum is costly and working with Medi-
care data benefits from an experienced analyst.
Welliver et al examined a decade of LUTS/BPH
management trends. They found that medicine use
increases with patient age while surgery decreases.
Younger men were more likely to elect treatments
which did not impact their sex lives. Understanding
the impacts of newer, minimally invasive BPH
therapies not yet covered in these data will be
exciting future work. We can look forward to UDA
projects to come which address critical questions
with big data.
Benjamin N. Breyer
Departments of Urology and Epidemiology and Biostatistics
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This excellent analysis shows practice management
trends and the impact of guidelines as they are is-
sued, reimbursements as they change, technology
adoption as well as the marketing power of industry.
Reimbursement and marketing power better
explain utilization trends. Graphs of various treat-
ments show the influence of industry to promote
each technology (fig. 3 in article). Open prostate and
TUIP had low numbers during the whole period,
reflecting limited promotion for these procedures.
Despite being minimally invasive with sexual
dysfunction and retrograde ejaculation rates as low
as those of other MIST procedures, TUIP never
gained increased use since industry did not actively
promote TUIP. Its reimbursement is also lower than
for other MISTs and TURP. Comparatively TURP
continues to enjoy high utilization but it was
impacted by the introduction of laser prostatectomy,
of which prostate photovaporization was the most
popular with solid marketing support by industry.
The waxing and waning trends of prostate photo-
vaporization seem to coincide and reflect periods
when technology was undergoing corporate transi-
tion instability while being acquired. Meanwhile,
TUNA and TUMT demonstrated growing utilization
in 2004 to 2008 with higher use in younger men.
These trends were driven by high reimbursements
and the combined marketing power of MIST com-
panies rather than a preference for MIST or for the
preservation of sexual function, especially since
MIST sexual function studies were poor in those
periods.
Despite similar reimbursement rates and sexual
side effects, the TUMT incidence was several times
higher than the TUNA rate because up to 5 TUMT
companies were marketing that technology vs 1 for
TUNA. The steady decline in thermotherapy is better
explained by decreased reimbursement and decreased
marketing. Recently TURP demonstrated a growing
increase in use, reflecting the introduction of bipolar
technology, which has slowly replaced monopolar
technology. Bipolar TURP is also advantageously
marketed and provided by major endoscopic com-
panies with access to the surgeon-physician.
The insights raised by these data are valuable
and may change how practice adopts technology in
the future.
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